If you want to know why drug research remains a slow and frustrating business even in this golden ageof molecular biology, look at the troubles Vertex Pharmaceuticals has gone through to devise a new drug to combat hepatitis C.
If you want to know why drug research remains a slow and frustrating business even in this golden ageof molecular biology, look at the troubles Vertex Pharmaceuticals (nasdaq: VRTX - news - people ) has gone through to devise a new drug to combat hepatitis C.